Edition:
United States

Galmed Pharmaceuticals Ltd (GLMD.OQ)

GLMD.OQ on NASDAQ Stock Exchange Capital Market

9.04USD
14 Dec 2017
Change (% chg)

$0.25 (+2.84%)
Prev Close
$8.79
Open
$8.92
Day's High
$9.72
Day's Low
$8.92
Volume
39,792
Avg. Vol
8,434
52-wk High
$9.72
52-wk Low
$3.04

Latest Key Developments (Source: Significant Developments)

Galmed Pharmaceuticals Q3 loss per share $0.23
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Galmed Pharmaceuticals Ltd :Galmed Pharmaceuticals reports third quarter 2017 financial results and provides business update.Q3 loss per share $0.23.Q3 earnings per share view $-0.26 -- Thomson Reuters I/B/E/S.Q3 revenue $300,000 versus I/B/E/S view $319,000.Galmed Pharmaceuticals - ‍cash, cash equivalents,marketable securities totaled $9.0 million as of Sept 30, compared to $15.5 million at December 31, 2016​.Galmed Pharmaceuticals Ltd - ‍Galmed believes that its cash balance will be sufficient to maintain its current operations through 2018​.  Full Article

Galmed Pharmaceuticals announces pricing of offering to existing investors, members of board
Thursday, 3 Aug 2017 04:52pm EDT 

Aug 3 (Reuters) - Galmed Pharmaceuticals Ltd :Galmed Pharmaceuticals announces pricing of offering of ordinary shares to existing investors and members of the board of directors.Galmed Pharmaceuticals - ‍entered into agreement for a registered direct offering of 332,038 ordinary shares at a price of $7.10 per share​.Galmed Pharmaceuticals expects to receive gross proceeds of about $2.7 million​.  Full Article

Galmed Pharmaceuticals reports Q2 loss per share of $0.22
Monday, 31 Jul 2017 06:00am EDT 

July 31 (Reuters) - Galmed Pharmaceuticals Ltd :Galmed Pharmaceuticals reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.22.Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Q2 revenue $300,000 versus I/B/E/S view $358,000.‍Cash, cash equivalents,marketable securities totaled $9.1 million as of June 30, 2017, compared to $15.5 million at December 31, 2016​.  Full Article

Galmed Pharma Q1 loss per share $0.26
Monday, 15 May 2017 08:00am EDT 

May 15 (Reuters) - Galmed Pharmaceuticals Ltd :Galmed pharmaceuticals reports first quarter 2017 financial results.Q1 loss per share $0.26.Q1 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.Q1 revenue $300,000 versus i/b/e/s view $258,000.Galmed pharmaceuticals - continues to believe that its cash balance will be sufficient to maintain its current operations through first half of 2018.  Full Article

Therapix Biosciences names Josh Blacher CFO
Wednesday, 3 May 2017 08:30am EDT 

May 3 (Reuters) - Therapix Biosciences Ltd ::Therapix Biosciences announces the appointment of Josh Blacher as chief financial officer.Prior to joining Therapix, Blacher served as Chief Financial Officer at Galmed Pharmaceuticals.  Full Article

Galmed Pharmaceuticals Q4 loss per share $0.40
Thursday, 23 Mar 2017 07:30am EDT 

Galmed Pharmaceuticals Ltd : Galmed Pharmaceuticals reports fourth quarter and full year 2016 financial results . Q4 loss per share $0.40 . Q4 earnings per share view $-0.30 -- Thomson Reuters I/B/E/S .Galmed Pharmaceuticals Ltd- cash and cash equivalents and marketable securities about $15.5 million as of Dec 31, 2016, versus about $23.0 million as of December 31, 2015.  Full Article

Galmed Pharmaceuticals signed agreement with University of California
Thursday, 22 Sep 2016 11:10am EDT 

Galmed Pharmaceuticals Ltd : Signed an investigator-initiated clinical trial agreement with University of California, San Diego, school of medicine .Artisan study is currently expected to be initiated in first half of 2017.  Full Article

Galmed Pharmaceuticals Q2 loss per share $0.39
Wednesday, 3 Aug 2016 08:00am EDT 

Galmed Pharmaceuticals Ltd : Q2 loss per share $0.39 .Expect that its cash balance will be sufficient to maintain its current operations through second half of 2017..  Full Article

Galmed and Samil Pharm sign deal for Aramchol(Tm) in Korea
Thursday, 28 Jul 2016 08:00am EDT 

Galmed Pharmaceuticals Ltd : Galmed Pharmaceuticals And Samil Pharm sign a license agreement for the commercialization of aramchol(tm) in Korea . Upon signing of agreement, samil will pay galmed an up-front fee of approximately $2.0 million .Samil has also agreed to pay additional clinical- and regulatory-based milestone payments, which may aggregate to $6.0 million.  Full Article

Galmed Pharmaceuticals says enters research collaboration agreement
Thursday, 30 Jun 2016 08:00am EDT 

Galmed Pharmaceuticals Ltd : Has right to enter into exclusive negotiations with Yeda to complete license agreement to commercialize diagnostic, prognostic tool for Aramchol .Galmed Pharmaceuticals and Weizmann Institute of Science to enter a research collaboration agreement to assess Aramchol(tm) effects on microbiome.  Full Article

BRIEF-Galmed Pharmaceuticals Q3 loss per share $0.23

* Galmed Pharmaceuticals reports third quarter 2017 financial results and provides business update